RxDoctor Payments Data

Steven Seizer, MD

Family Medicine · Santa Monica, CANPI 1942236906

Payments from drug & device makers

$5,546in general payments, 2019–2025

Across 221 payments — averaging $25.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$750
  • Lilly USA, LLC$629
  • Novo Nordisk$601
  • AstraZeneca$507
  • Bayer$409
  • AbbVie$360
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$5,48299%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,546 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$121,798
Medicare patients
322
Services billed
1,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$50,182
EliquisApixaban28$28,510
WegovySemaglutide18$23,784
JardianceEmpagliflozin11$18,220
MounjaroTirzepatide13$17,330
JanuviaSitagliptin Phosphate11$16,781
Atorvastatin Calcium383$5,562
Wixela InhubFluticasone Propion/Salmeterol14$3,070
Losartan Potassium131$2,381
Citalopram HbrCitalopram Hydrobromide17$2,251
Rosuvastatin Calcium97$2,040
SynthroidLevothyroxine Sodium56$1,862
Omeprazole72$1,534
Testosterone15$1,426
Gabapentin86$1,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$601$73,96571 claims
PfizerEliquis$324$28,51028 claims
Boehringer IngelheimJardiance$47$18,22011 claims
Lilly USA, LLCMounjaro$629$17,33013 claims
AbbVieSynthroid$360$1,86256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →